U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236190) titled 'Biomarker-based Trial of NPC-1 for Alzheimer's Pathology' on Oct. 28.
Brief Summary: The goal of this early phase, open-label, single arm clinical trial is to determine the 6-month effects and tolerability of NPC1 (parthenolide and ipriflavone) on biomarkers of Alzheimer's Disease among adults with objective indicators of seeding AD pathology that also have subjective cognitive concerns, Mild Cognitive Impairment, or Alzheimer's Disease (AD)
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Mild Cognitive Impairment (MCI)
Subjective Cognitive Complaints (SCCs)
Intervention:
DRUG: NPC1
NPC1 (...